Sunitinib is an oral multikinase inhibitor that blocks the vascular endothelial growth factor
receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-kit …

Sunitinib is an oral multikinase inhibitor that blocks the vascular endothelial growth factor
receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-kit …

Background: Until recently, few treatments were available for renal cell carcinoma (RCC)
and gastrointestinal stromal tumors (GIST). Several targeted agents inhibiting key …

Background: Sunitinib was approved by the US Food and Drug Administration (FDA) on
January 26, 2006, for the treatment of metastatic renal cell carcinoma (mRCC) and …

Abstract▴ Sunitinib and its active metabolite (SU012662) are selective inhibitors of multiple
receptor tyrosine kinases associated with tumour growth and angiogenesis.▴ The clinical …

Sunitinib malate is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and
antiangiogenic activities. Sunitinib was recently approved in first-line treatment for patients …

Sunitinib is a novel, oral, multi-targeted tyrosine kinase inhibitor with antiproliferative effects
against cancer cells and antiangiogenic properties. Sunitinib was recently approved for the …

Recently, there has been a growing interest in understanding the role of receptor tyrosine
kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet …

Tyrosine kinase receptors (RTKs) are a heterogeneous group of transmembrane proteins
involved in signal transduction. These receptors are expressed in many different cells and …

Sunitinib is a small-molecule inhibitor of several receptor tyrosine kinases relevant to tumor
angiogenesis, including the vascular endothelial growth factor (VEGF) receptor. Potent …